Naloxegol Phase III Win Muted by FDA's CV Stance
By Marie Powers
Monday, November 12, 2012
The FDA threw a wrench into the fireworks for AstraZeneca plc and Nektar Therapeutics Inc. after the companies reported positive top-line findings from two Phase III studies and a safety extension trial of naloxegol (NKTR-118) in noncancer-related pain and opioid-induced constipation (OIC).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.